http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Gisela MÜLLER-PLATH,David JUNG,Martin MÜLLER 국제이네비해양경제학회 2018 International Journal of e-Navigation and Maritime Vol.10 No.1
Electronic Charting systems (ECS) in yachting and boating are the non-professional counterparts to ECDIS in commercial shipping. In the absence of legal regulations on design and use, a wide variety of products have de-veloped. Their usability is not only safety critical but often even determines whether navigation functions like route building or track recording are used at all. With two empirical studies employing standard usability meth-ods from human factors research, we assessed the usability of a variety of current ECSs on a sailing yacht. In study 1, nine usability experts conducted multimethod analyses while sailing in typical cruising areas on sea. Building on the results, a standardized user test was designed and carried out with 12 prototypical users plus 3 usability experts in inland waters (study 2). Finally, a set of 38 design and usability guidelines were formulated. The guidelines may not only help boat owners and charter companies in selecting a current market product but also aid manufacturers in designing their future products. Contributions: David Jung (study 1) and Martin Müller (study 2) conducted the studies and formulated the guide-lines. Gisela Müller-Plath designed and managed the research project ANeMoS (Analysing Use and Impact of NewMedia on Sailboats) which the present work is part of, commanded the sailing yacht, and wrote the paper.
Mü,ller, Martin C.,Cortes, Jorge E.,Kim, Dong-Wook,Druker, Brian J.,Erben, Philipp,Pasquini, Ricardo,Branford, Susan,Hughes, Timothy P.,Radich, Jerald P.,Ploughman, Lynn,Mukhopadhyay, Jaydip,Hochh American Society of Hematology 2009 Blood Vol.114 No.24
<B>Abstract</B><P>Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase 2/3 trials with chronic-phase chronic myeloid leukemia with or without BCR-ABL mutations after prior imatinib. Among 1043 patients, 39% had a preexisting BCR-ABL mutation, including 48% of 805 patients with imatinib resistance or suboptimal response. Sixty-threedifferent BCR-ABL mutations affecting 49 amino acids were detected at baseline, with G250, M351, M244, and F359 most frequently affected. After 2 years of follow-up, dasatinib treatment of imatinib-resistant patients with or without a mutation resulted in notable response rates (complete cytogenetic response: 43% vs 47%) and durable progression-free survival (70% vs 80%). High response rates were achieved with different mutations except T315I, including highly imatinib-resistant mutations in the P-loop region. Impaired responses were observed with some mutations with a dasatinib median inhibitory concentration (IC50) greater than 3nM; among patients with mutations with lower or unknown IC50, efficacy was comparable with those with no mutation. Overall, dasatinib has durable efficacy in patients with or without BCR-ABL mutations. All trials were registered at http://www.clinicaltrials.gov as NCT00123474, NCT00101660, and NCT00103844.</P>
Reliability and risk treatment centered maintenance
Martin Pexa,Tomáš Hladík,Zdeněk Aleš,Václav Legát,Vít Havlů,Miroslav Müller,Petr Valášek 대한기계학회 2014 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.28 No.10
We propose a new methodology for application of well-known tools – RCM, RBI and SIFpro – with the aim to treat risks by means ofsuitable maintenance. The basis of the new methodology is the complex application of all three methods at the same time and not separatelyas is typical today. The proposed methodology suggests having just one managing team for reliability and risk treatment centredmaintenance (RRTCM), employing existing RCM, RBI, and SIFpro tools concurrently. This approach allows for significant reduction ofengineering activities’ duration. In the proposed methodology these activities are staged into five phases and structured to eliminate allduplication resulting from separate application of the three tools. The newly proposed methodology saves 45% to 50% of the engineeringworkload and adequate significant financial savings.
Afat, Saif,Brockmann, Carolin,Nikoubashman, Omid,Mü,ller, Marguerite,Thierfelder, Kolja M.,Brockmann, Marc A.,Nikolaou, Konstantin,Wiesmann, Martin,Kim, Jong Hyo,Othman, Ahmed E. Radiological Society of North America 2018 Radiology Vol.287 No.2
<P>Conclusion: The results suggest that radiation dose reduction to 40% of original dose levels (tube current-time product, 72 mAs) may be performed in VP CT imaging of patients with aneurysmal subarachnoid hemorrhage without compromising the diagnostic accuracy regarding detection of cerebral perfusion impairment indicating vasospasm. (C)RSNA, 2018</P>
Hughes, Timothy,Saglio, Giuseppe,Branford, Susan,Soverini, Simona,Kim, Dong-Wook,Mü,ller, Martin C,Martinelli, Giovanni,Cortes, Jorge,Beppu, Lan,Gottardi, Enrico,Kim, Dongho,Erben, Philipp,Shou, Y Grune Stratton ; American Society of Clinical Onco 2009 Journal of clinical oncology Vol.27 No.25
<P>PURPOSE: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy. In this subanalysis of a phase II study of nilotinib in patients with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact of baseline and newly detectable BCR-ABL mutations were assessed. PATIENTS AND METHODS: Baseline mutation data were assessed in 281 (88%) of 321 patients with CML-CP in the phase II nilotinib registration trial. RESULTS: Among imatinib-resistant patients, the frequency of mutations at baseline was 55%. After 12 months of therapy, major cytogenetic response (MCyR) was achieved in 60%, complete cytogenetic response (CCyR) in 40%, and major molecular response (MMR) in 29% of patients without baseline mutations versus 49% (P = .145), 32% (P = .285), and 22% (P = .366), respectively, of patients with mutations. Responses in patients who harbored mutations with high in vitro sensitivity to nilotinib (50% inhibitory concentration [IC(50)] <or= 150 nM) or mutations with unknown nilotinib sensitivity were equivalent to those responses for patients without mutations (not significant). Patients with mutations that were less sensitive to nilotinib in vitro (IC(50) > 150 nM; Y253H, E255V/K, F359V/C) had less favorable responses, as 13%, 43%, and 9% of patients with each of these mutations, respectively, achieved MCyR; none achieved CCyR. CONCLUSION: For most patients with imatinib resistance and with mutations, nilotinib offers a substantial probability of response. However, mutational status at baseline may influence response. Less sensitive mutations that occurred at three residues defined in this study, as well as the T315I mutation, may be associated with less favorable responses to nilotinib.</P>